A method to estimate the incidence of transfusion reactions for transfusion-treated diseases in Chinese hospitals

Feng Lin [1], Xue Tian [2], Yonghua Yin[3], Zhong Liu[4]

Institute of blood transfusion, Key laboratory of transfusion adverse reactions,

Chinese academy of medical science and Peking union medical college

No.26 Huacai Road, Chengdu, 610052, People's Republic of China

Abstract: Although transfusion reactions are directly related to transfusion components, transfusion components are clinically related to the diseases afflicting patients. As some transfusion reactions can be life-threatening, estimating the incidence of transfusion reactions (which, in this study, are strictly defined as allergic and febrile non-haemolytic transfusion reactions) of certain categories of diseases is helpful for clinicians. According to the reported blood use of specific departments, the numbers of transfusion patients in these departments can be estimated. By the Association rule mining algorithm, the categories of diseases that often correlate with transfusion reactions have been screened for. It is found that the diseases belonging to C00-C97, D00-D48, D50-D89, K00-K93, N00-N99 and O00-O99 (ICD-10) often correlate with transfusion reactions. Platelet transfusion patients whose diseases belong to C00-C97 encounter transfusion reactions with an incidence of about 1%, which is much higher than the average. The incidence of transfusion reactions in patients whose diseases belong to K00-K93 —who undergo plasma transfusions —might be higher than the average, as the lower bound of this incidence is equivalent to the average incidence. Based on this study, it is suggested that attention be paid to patients whose diseases belong to C00-C97 —who undergo platelet transfusions —to prevent them from experiencing allergic transfusion reactions.

Key words: Transfusion reaction; Association rule mining algorithm; Incidence of transfusion reaction

1 Introduction

Transfusions are a kind of therapeutic procedure performed on hospitalized patients [1–4]. It is well known that errors in blood transfusion practices can lead to serious consequences for recipients in terms

[1]E-mail: `linfeng@ibt.pumc.edu.cn`
[2]E-mail: `tianxuexzh@student.pumc.edu.cn`, Equal contribution with the first author
[3]E-mail: `yhyin.ibt@gmail.com`
[4]E-mail: `liuz@ibt.pumc.edu.cn`

of morbidity and mortality [5–8]. The morbidity or mortality caused by transfusions are called adverse transfusion reactions or transfusion reactions (TRs). The incidence of transfusion reactions is about 0.2% [9,10]. Most transfusion reactions are related to immune reactions [11]. Allergic and febrile nonhaemolytic transfusion reactions (FNHTR) are the most common transfusion reactions, and clinicians most often encounter this type. In this study, allergic and FNHTRs constitute a sufficiently large sample size, so in this paper we only focus on these two kinds of transfusion reactions.

For clinicians, attention must be paid to the diseases that afflict their patients. They make decisions about whether their patients need transfusions according to their patients' conditions. As some mechanisms of TR still remain unknown [12–16], estimating the incidence of transfusion reactions corresponding to certain of diseases is better than judging the incidence of transfusion reactions by average incidence. This is helpful for clinicians in preventing transfusion patients from experiencing transfusion reactions.

Though the numbers of transfusion patients in certain disease categories are supplied, they can be roughly estimated by the blood use of various departments. Information on transfusion reactions among patients (including the departments in which they were in, their categories of TRs and the diseases afflicting them) has already been collected in a database. This means that an interval or at least a lower bound for such incidence can be estimated. To screen specific categories of diseases that often correlate with transfusion reactions, Association rule mining algorithm [17–23] is used. According to the numbers of samples that belong to the specific categories of diseases screened by the Association mining rule algorithm, lower bounds or intervals of the incidence of transfusion reactions for specific categories of diseases can be estimated.

2 Materials and methods

2.1 Ethical approval

All patients involve in the study had given written informed consent by participating hospitals. The current project was approved by the review board of the Research Ethics Committee of Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College on September 18, 2016 (registration number 2016017).

2.2 Materials

Samples of transfusion reaction patients are supplied by the Key Laboratory of Adverse Transfusion Reactions (the Key Laboratory). The Key Laboratory collects data on clinical cases of transfusion reactions. A total of 79 hospitals have joined the Key Laboratory. Apart from Tibet, the samples supplied by these hospitals are representative of all transfusion reaction patients in the Chinese mainland.

From May 2018 to June 2019, 1255 cases were collected. In this study, the sample size for allergy and FNHTR was large enough for statistical research. Among the 1255 cases, only 839 cases appeared to be allergy or FNHTR. According to the clinical diagnoses, there were 754 confirmed cases. Table 1 shows the

number of transfusion patients and the total quantity of transfusion components.

Table 1: The total quantity of transfusion patient and blood components

	Number	Transfusions	Red blood cells	Plasma	Concentrated platelets	Apheresis platelets	Cryoprecipitation
Total	681077	1188380	1264293.85	136100947.38	10315.5	240190.1	1545916.2

The data in Table 1 only supply the number of transfusion patients, whereas the numbers of patients who belong to certain categories of diseases that required transfusions have not been supplied. Estimating the incidence of transfusion reactions requires two kinds of information: the number of transfusion patients who belonged to a specific category of diseases and how many of them had transfusion reactions. The former has not been supplied, so it must be estimated. The latter, however, has been supplied by the Key Laboratory. The "Chinese Clinical Blood Use Research Report (2016)" is helpful for making this estimate. This report was completed in 2017, and it reported the proportion of blood use in the departments shown in Table 2.

Table 2: Proportion of blood use in each department

Department	Red blood cells	Plasma	Platelets	Cryoprecipitation
Internal medicine	24%	27%	48%	15%
Surgery	39%	42%	17%	23%
Gynaecology and obstetrics	6%	3%	4%	3%
ICU	9%	15%	6%	15%
Paediatrics	3%	3%	6%	34%
Others	19%	10%	19%	8%

2.3 Estimation of the number of transfusion patients

Following Table 2, we first estimated the average blood dosage in each department. With the average dosage, the number of transfusion patients in each department could be estimated. According to the transfusion dosage records supplied by the hospitals, the estimated average transfusion dosages are shown in Table 3.

According to Table 3 and tables 1-2, the numbers of transfusion patients in each department can be estimated, as shown in Table 4.

Table 4 supplies the base information on the numbers of transfusion patients. The total numbers of transfusion patients shown in Table 4 are larger than the total numbers supplied by Table 1. The reason for this is that some patients received transfusions of more than one kind of component, and some transfusions were stopped when acute TRs occurred. These situations led to errors regarding average dosage estimates. The estimated numbers were larger than the numbers of transfusions in Table 1. By calculation, the actual

Table 3: Average dosage estimated in each of the department

Department	Red blood cells	Plasma	Platelets	Cryoprecipitation
Internal medicine	4.63	1411	3.86	5.02
Surgery	3.92	707	0.11	1.11
Gynaecology and obstetrics	4.17	554	2	9.4
ICU	7.19	1475	6.78	220
Paediatrics	2.54	162	2.86	6.95
Others	4.46	777	4.5	3.14

Table 4: Estimated number of transfusion patients in each of the department

Department	Red blood cells	Plasma	Platelets	Cryoprecipitation
Internal medicine	65535	26043	31150	46192
Surgery	125784	80852	387145	320324
Gynaecology and obstetrics	18191	7370	5010	4933
ICU	15825	13840	2216	1054
Paediatrics	14932	25203	5255	75627
Others	53860	17516	10576	39386

number of transfusions was 0.85 times the estimated number of transfusions. Though we are not able to know the exact numbers of transfusion patients who were being treated for certain diseases, the numbers of transfusion patients in each of the departments already give intervals on the numbers of transfusion patients who were suffering certain categories of diseases.

2.4 Estimation of the incidence of transfusion reaction

By intuition, some categories of diseases result in transfusion reactions more frequently. The transfusion component used is associated with the patient's condition, and the patient's condition is related to the disease for which the patient is being treated. The causality is as such: the disease that the patient is being treated for determines the transfusion component that the clinician chooses to use, and the transfusion component and the patient's condition lead to certain transfusion reactions. The causes that lead to transfusion reactions form a chain of causality. For each TR patient, a chain of causality can be determined.

Transfusion patients are divided into groups according to the department classifications in tables 2-4. The causes of each of the samples are divided into four parts: the disease that the patient was being treated for, the reason for transfusion, the immune history of the patient and the transfusion component that the patient received. Information on all samples was supplied by the Key Laboratory. A schematic graph of the relation of causes is shown in Figure 1



Figure 1: The causality network of transfusion reaction

The support and confidence of the combination of these causes can be determined by the Apriori algorithm. The larger the support is, the stronger the association with the disease and transfusion reaction. Collecting frequently encountered combinations of causes, it is possible to estimate the incidence of transfusion reactions for a certain category of diseases.

The minimal support in the Apriori algorithm is set to 10^{-4}. This means that as long as a chain of causality is found, this chain of causality is considered to be associated with transfusion reactions. But in practice we choose a minimum support as follows: if the support of the chain of causality is lower than 0.05 in the combination of these four causes, or if it is lower than 0.04 in a combination of four causes plus a result, this causality chain is not taken into consideration. The reason is that the sample sizes of transfusion reactions in each of the departments are not as large as the sample sizes of customer purchasing behavior. Though a low support of a certain kind of combination might indicate a causality chain, it is difficult to conclude that such a combination is of statistical significance.

3 Results

The estimated incidence of transfusion reactions in each department is shown in tables 5-10. The classification of diseases accords with the International Classification of Diseases, 10th revision (ICD-10). By Association rule mining algorithm, seven kinds of diseases that would frequently result in transfusion reactions were found. According to reference [24–27] (figure 3 in [28]), the incidence for cancer in China is 0.2%. In the department of internal medicine, according to the records supplied by the Key Laboratory, of all 408 patients that had transfusion reactions (allergy or FNHTR), 137 were cancer patients. It is reasonable to estimate that in the department of internal medicine, 20% of all patients are cancer patients. And according to the data supplied by the Key Laboratory, in the department of internal medicine, nearly $1/3(33 out of 109)$ of the patients whose diseases belonged to D50-D89 also had cancer. That is why an upper bound for the incidence of transfusion reactions with diseases belonging to C00-C99 and D50-D89 can be estimated in the department of internal medicine.

Remarks: In Table 5, myelosuppression after chemotherapy can result in thrombocytopenia, so the range of ATR patients belonging to C00-C97 is estimated as $(64, 89)$. Similarly, the range for ATR patients belonging to D50-D89 is $(30, 49)$ (according to Table 11). The total numbers of transfusion patients who received transfusions of a certain component are shown in Table 4. It has been assumed that 20% of the patients in the department of internal medicine belonged to C00-C93. And since 1/3 of the patients

Table 5: The incidence of transfusion reaction in the internal department

ICD	Lower bound of incidence	Upper bound of incidence	Component	Category of reaction
C00-C97	0.0020	0.0143	Platelets	Allergy
D50-D89	0.00096	0.0026	Platelets	Allergy
K00-K93	0.0019	-	Plasma	Allergy

Table 6: The incidence of transfusion reaction in the surgery department

ICD	Lower bound of incidence	Upper bound of incidence	Component	Category of reaction
K00-K93	0.0001	-	Plasma	Allergy
S00-T98	9.89×10^{-5}	-	Plasma	Allergy

Table 7: The incidence of transfusion reaction in the gynaecology and obstetrics department

ICD	Lower bound of incidence	Upper bound of incidence	Component	Category of reaction
D00-D48	0.0001	-	Red blood cells	FNHTR
N00-N99	0.0001	-	Red blood cells	FNHTR
O00-O99	0.0001	-	Red blood cells	FNHTR
D50-D89	0.0001	-	Red blood cells	Allergy
O00-O99	0.0003	-	Red blood cells	Allergy
O00-O99	0.0016	-	Plasma	Allergy

Table 8: The incidence of transfusion reaction in the ICU department

ICD	Lower bound of incidence	Upper bound of incidence	Component	Category of reaction
K00-K93	0.0002	-	Red blood cells	Allergy
K00-K93	0.0004	-	Plasma	Allergy

Table 9: The incidence of transfusion reaction in the paediatrics department

ICD	Lower bound of incidence	Upper bound of incidence	Component	Category of reaction
C00-C97	0.01	-	Platelets	Allergy
D50-D89	0.002	-	Platelets	Allergy

Table 10: The incidence of transfusion reaction in the other department

ICD	Lower bound of incidence	Upper bound of incidence	Component	Category of reaction
C00-C97	0.0001	0.00056	Red blood cells	FNHTR
D50-D89	0.0001	-	Red blood cells	FNHTR
N00-N99	0.0001	-	Red blood cells	Allergy
C00-C97	0.0003	0.001	Plasma	Allergy

whose diseases belonged to D50-D89 also had cancer, it could be assumed that $0.3 \times 20\% = 6\%$ of the patients in the department of internal medicine belonged to D50-D89. In Table 7,bleeding would result in anemia (according to Table 13), so the range for ATR patients belonging to O00-D99 is $(12, 15)$, but the patients who needed plasma transfusions in the gynecology and obstetrics department did not all belong to O00-O99. So, the upper bound for this incidence could not be estimated. In Table 9, the lower bound for the number of cancer patients is estimated as 53. Although, according to Table 15, bleeding is related to thrombocytopenia, according to the raw data supplied by the Key Laboratory, only one sample showed both bleeding and thrombocytopenia. In Table 10, it is also assumed that 20% of the patients in this department belonged to C00-C93.

Detailed information on the supports and combinations of causes are shown in tables 11-16, which also show the supports of combinations of causes in each department. These tables supply support information for tables 5-10. According to tables 11-16, apart from the gynecology and obstetrics department, the diseases that belong to C00-C97, K00-K93 and D50-D89 result in transfusion reactions frequently. The transfusion components that most probably cause allergies are platelets and plasma. FNHTR caused by the red blood cell component mainly occurs in the gynecology and obstetrics department.

The guidelines on transfusion reactions [8, 29–31] mention that immune history, especially transfusion history, is related to transfusion reactions, and the causality chains found in tables 11-16 are consistent with that view. Patients whose diseases belonged to the classifications C00-C97, D50-D89 or K00-K93 often received transfusions. That these diseases result in repeated transfusions may be a cause of these transfusion reactions.

Table 11: The support of the combination of the causes in the internal medicine department

Total samples	361	
Combination	Support	Samples
K00-K93, Coagulable abnormality, Plasma, Allergy	0.135734072	49
C00-C97, Myelosuppression, Platelets, Allergy	0.108033241	39
D50-D89, Myelosuppression, Platelets, Allergy	0.083102493	30
C00-C97, Coagulable abnormality, Platelets, Allergy	0.069252078	25
C00-C97, Thrombocytopenia, Platelets, Allergy	0.069252078	25
D50-D89, Thrombocytopenia, Platelets, Allergy	0.052631579	19
K00-K93, Transfusion history, Plasma, Allergy	0.074792244	27
C00-C97, Transfusion history, Platelets, Allergy	0.163434903	59
C00-C97, Transfusion reaction history, Platelet, Allergy	0.066481994	24
C00-C97, Allergy history, Platelets, Allergy	0.063711911	23
D50-D89, Transfusion history, Platelets, Allergy	0.110803324	40
D50-D89, Transfusion history reaction, Platelet, Allergy	0.055401662	20
K00-K93, Coagulable abnormality, Transfusion history, Plasma, Allergy	0.069252078	25
C00-C97, Myelosuppression, Transfusion history, Platelets, Allergy	0.077562327	28
C00-C97, Myelosuppression, Transfusion reaction history, Platelet, Allergy	0.052631579	19
C00-C97, Myelosuppression, Allergy history, Platelets, Allergy	0.052631579	19
D50-D89, Myelosuppression, Transfusion history, Platelets, Allergy	0.060941828	22
D50-D89, Myelosuppression, Transfusion reaction history, Platelet, Allergy	0.04432133	16
C00-C97, Thrombocytopenia, Transfusion history, Platelets, Allergy	0.041551247	15

Myelosuppression means myelosuppression after chemotherapy

Table 12: The support of the combination of the causes in the surgery department

Total samples	126	
Combination	Support	Samples
K00-K93, Coagulable abnormality, Plasma, Allergy	0.079365079	10
S00-T98, Coagulable abnormality, Plasma, Allergy	0.063492063	8

Table 13: The support of the combination of the causes in the gynaecology and obstetrics department

Total samples	40	
Combination	Support	Samples
D00-D48, Anemia, Red blood cells, Allergy	0.05	2
O00-O99, Anemia, Red blood cells, Allergy	0.15	6
O00-O99, Coagulable abnormality, Plasma, Allergy	0.175	7
O00-O99, Anemia, Plasma, Allergy	0.05	2
O00-O99, Perioperative blood transfusion, Plasma, Allergy	0.075	3
O00-O99, Bleeding, Plasma, Allergy	0.075	3
D50-D89, Anemia, Red blood cells, FNHTR	0.05	2
N00-N99, Anemia, Red blood cells, FNHTR	0.05	2
O00-O99, Anemia, Red blood cells, FNHTR	0.05	2
D00-D48, Transfusion history, Red blood cells, Allergy	0.05	2
D00-D48, Transfusion reaction history, Red blood cells, Allergy	0.05	2
O00-O99, Pregnancy history, Red blood cells, Allergy	0.075	3
O00-O99, Transfusion history, Plasma, Allergy	0.125	5
O00-O99, Pregnancy history, Plasma, Allergy	0.325	13
O00-O99, Pregnancy history, Red blood cells, FNHTR	0.075	3
O00-O99, Pregnancy history, Plasma, FNHTR	0.05	2
D00-D48, Anemia, Transfusion history, Red blood cells, Allergy	0.05	2
D00-D48, Anemia, Transfusion history reaction, Red blood cells, Allergy	0.05	2
O00-O99, Anemia, Pregnancy history, Red blood cells, Allergy	0.075	4
O00-O99, Coagulable abnormality, Transfusion history, Plasma, Allergy	0.1	4
O00-O99, Coagulable abnormality, Pregnancy history, Plasma, Allergy	0.15	6
O00-O99, Perioperative blood transfusion, Pregnancy history, Plasma, Allergy	0.075	3
O00-O99, Bleeding, Pregnancy history, Plasma, Allergy	0.05	2

Table 14: The support of the combination of the causes in the ICU department

Total samples	55	
Combination	Support	Samples
K00-K93, Coagulable abnormality, Red blood cells, Allergy	0.054545455	3
K00-K93, Coagulable abnormality, Plasma, Allergy	0.090909091	5
K00-K93, Transfusion history, Red blood cells, Allergy	0.054545455	3
K00-K93, Transfusion history, Plasma, Allergy	0.054545455	3
K00-K93, Pregnancy history, Plasma, Allergy	0.054545455	3
K00-K93, Coagulable abnormality, Transfusion history, Plasma, Allergy	0.054545455	3

Table 15: The support of the combination of the causes in the paediatrics department

Total samples	88	
Combination	Support	Samples
C00-C97, Coagulable abnormality, Platelets, Allergy	0.238636364	21
D50-D89, Coagulable abnormality, Platelets, Allergy	0.102272727	9
C00-C97, Thrombocytopenia, Platelets, Allergy	0.170454545	15
C00-C97, Bleeding, Platelet, Allergy	0.204545455	18
C00-C97, Transfusion history, Platelets, Allergy	0.465909091	41
C00-C97, Transfusion reaction history, Platelets, Allergy	0.136363636	12
C00-C97, Allergy history, Platelets, Allergy	0.102272727	9
D50-D89, Transfusion history, Platelets, Allergy	0.159090909	14
C00-C97, Coagulable abnormality, Transfusion history, Platelets, Allergy	0.227272727	20
C00-C97, Coagulable abnormality, Transfusion reaction history, Platelets, Allergy	0.090909091	8
C00-C97, Coagulable abnormality, Allergy history, Platelets, Allergy	0.079545455	7
D50-D89, Coagulable abnormality, Transfusion history, Platelets, Allergy	0.090909091	8
C00-C97, Thrombocytopenia, Transfusion history, Platelets, Allergy	0.079545455	7
C00-C97, Bleeding, Transfusion history, Platelets, Allergy	0.147727273	13
D50-D89, Bleeding, Transfusion history, Platelets, Allergy	0.045454545	4

Table 16: The support of the combination of the causes in the other department

Total samples	84	
Combination	Support	Samples
N00-N99, Anemia, Red blood cells, Allergy	0.095238095	8
C00-C97, Coagulable abnormality, Plasma, Allergy	0.05952381	5
C00-C97, Anemia, Red blood cells, FNHTR	0.071428571	6
D50-D89, Anemia, Red blood cells, FNHTR	0.071428571	6
N00-N99, Pregnancy history, Red blood cells, Allergy	0.095238095	8
C00-C97, Pregnancy history, Plasma, Allergy	0.05952381	5
C00-C97, Transfusion history, Platelets, Allergy	0.095238095	8
C00-C97, Pregnancy history, Platelets, Allergy	0.095238095	8
C00-C97, Transfusion history, Red blood cells, FNHTR	0.05952381	5
N00-N99, Anemia, Transfusion history, Red blood cells, Allergy	0.047619048	4
N00-N99, Anemia, Pregnancy history, Red blood cells, Allergy	0.083333333	7
C00-C97, Coagulable abnormality, Pregnancy history, Plasma, Allergy	0.05952381	5
C00-C97, Anemia, Transfusion history, Red blood cells, FNHTR	0.05952381	5
D50-D89, Anemia, Transfusion history, Red blood cells, FNHTR	0.047619048	4
D50-D89, Anemia, Pregnancy history, Red blood cells, FNHTR	0.047619048	4

4 Conclusion and Discussion

As has already been discussed in Section 3, the diseases that frequently correlated with transfusion reactions most probably belonged to the following classifications: C00-C97, K00-K93 and D50-D89. According to tables 5-10, the incidence of transfusion reactions is high in the group of cancer patients, especially when platelets are transfused. In the pediatrics department, transfusion reactions among cancer patients were nearly ten times the average incidence. Patients whose diseases belonged to the classifications C00-C97, D50-D89 or K00-K93 may have received repeated transfusions. That these diseases resulted in repeated transfusions may have been a cause of these transfusion reactions. This result is consistent with the previous study.

Unlike a study seeking to discover information about mechanisms of action via experimental design, the information from this study was extracted from a database. This information shows that attention should be paid to cancer patients who need platelet transfusions. So far, the sample sizes for transfusion reactions are not large. Provided sample sizes are large enough, information on transfusion reactions, such as transfusion-associated circulatory overload and transfusion-related acute lung injury, which might be related to certain kinds of diseases, can be extracted in a similar fashion. This study only demonstrated a method to estimate the incidence of transfusion reactions. If information on the numbers of transfusion patients who were treated for certain kinds of diseases becomes known, the estimates can be made more accurate.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was supported by the Fundamental Research Funds for the Central Universities (3332019170), the CAMS Innovation Fund for Medical Sciences (2016-I2M-3-024) and the Non-profit Central Research Institute Fund of the Chinese Academy of Medical Sciences (2018PT32016).

References

[1] John V. Cox, E. Steane, G. Cunningham, and Eugene P. Frenkel. Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. *Archives of Internal Medicine*, 148(11):2485–2489, 1988.

[2] Nancy M. Heddle. Pathophysiology of febrile nonhemolytic transfusion reactions. *Current Opinion in Hematology*, 6(6):420–426, 1999.

[3] Karen E. King, R. Sue Shirey, Sandra K. Thoman, Debra Bensen-Kennedy, and Paul M. Ness. Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to rbcs. *Transfusion*, 44(1):25–29, 2010.

[4] Sandhya R Panch, Celina Montemayor-Garcia, and Harvey G Klein. Hemolytic transfusion reactions. *New England Journal of Medicine*, 381(2):150–162, 2019.

[5] Jeannie L. Callum, Harold S. Kaplan, Lisa L. Merkley, Peter H. Pinkerton, Barbara Fastman Rabin, R. Romans, A. S. Coovadla, and Marciano D. Reis. Near-miss event reporting for transfusion medicine: Will it help us get the right blood to the right patient? *Transfusion*, 41(9):27S–27S, 2001.

[6] Harold S. Kaplan. Getting the right blood to the right patient: the contribution of near-miss event reporting and barrier analysis. *Transfusion Clinique Et Biologique Journal De La SociétéFranaise De Transfusion Sanguine*, 12(5):380–384, 2005.

[7] Alison Watt, Thomas Jun Gyuchan, and Waterson Patrick. Noticing errors in blood transfusion prevents harm to patients. In *Healthcare systems Ergonomics and Patient Safety Conference*, pages 377–382, 2016.

[8] World Health Organisation. Clinical transfusion practice guidelines for medical interns. `https://www.who.int/bloodsafety/transfusion_services/ClinicalTransfusionPracticeGuidelinesforMedicalInternsBangladesh.pdf`.

[9] Erik J. Uhlmann, Elizabeth Isgriggs, Mary Wallhermfechtel, and Lawrence T. Goodnough. Prestorage universal wbc reduction of rbc units does not affect the incidence of transfusion reactions. *Transfusion*, 41(8):997–1000, 2001.

[10] Jeanne E Hendrickson, Nareg H Roubinian, Dhuly Chowdhury, Don Brambilla, Edward L Murphy, Yanyun Wu, Paul M Ness, Eric A Gehrie, Edward L Snyder, George R Hauser, Jerome L. Gottschall, Steve Kleinman, Ram Kakaiya, and Ronald G. Strauss. Incidence of transfusion reactions: a multicenter study utilizing systematic active surveillance and expert adjudication. *Transfusion*, 56(10):2587–2596, 2016.

[11] Meghan Delaney, Silvano Wendel, Rachel S Bercovitz, Joan Cid, Claudia Cohn, DunbarNancy M Dunbar, Torunn O Apelseth, Mark Popovsky, Simon J Stanworth, Alan Tinmouth, Leo Van De Watering, Jonathan H Waters, Mark Yazer, and Alyssa Ziman. Transfusion reactions: prevention, diagnosis, and treatment. *The Lancet*, 388(10061):2825 – 2836, 2016.

[12] Patricia M. Kopko and Paul V. Holland. Mechanisms of severe transfusion reactions. *Transfusion Clinique et Biologique*, 8(3):278–281, 2001.

[13] Ronald E. Domen and Gerald A. Hoeltge. Allergic transfusion reactions. *Archives of Pathology and Laboratory Medicine*, (3):316–320, 2003.

[14] William J. Savage, Aaron A. R. Tobian, Jessica H. Savage, Robert A. Wood, John T. Schroeder, and Paul M. Ness. Scratching the surface of allergic transfusion reactions. *Transfusion*, 2013.

[15] Olivier Garraud. How to reposition the benefice-risk balance to safely transfuse patients in non-vital situations? *Transfusion Clinique et Biologique*, 26(3):171 – 173, 2019.

[16] William J Savage. Allergic transfusion reactions. In *Transfusion Medicine and Hemostasis*, pages 389–392. Elsevier, 2019.

[17] Agrawal Rakesh, Imielinski Tomasz, and Swami Arun. Mining association rules between sets of items in large databases, sigmod conference. In *International Conference on Management of Data*, 1993.

[18] Rakesh Agrawal and Ramakrishnan Srikant. Fast algorithms for mining association rules. In *Proceedings of the 20th International Conference on Very Large Data Bases*, 1994.

[19] Maurice Houtsma and Swami Arun. Set oriented mining of association rules. In *Proc of International Conference on Data Engineering*, 1995.

[20] Rakesh Agrawal and Ramakrishnan Srikant. *Fast algorithms for mining association rules and sequential patterns*. Morgan Kaufmann Publishers Inc., 1996.

[21] Akihiro Inokuchi. An apriori-based algorithm for mining frequent substructures from graph data. 2000.

[22] Kaur Gagandeep and Aggarwal Shruti. Performance analysis of association rule mining algorithms. In *International Journal of Advanced Research in Computer Science and Software Engineering*, volume 3, 2013.

[23] T. Ramraj and R. Prabhakar. Frequent subgraph mining algorithms-a survey. *Procedia Computer ence*, 47:197–204, 2015.

[24] Fangliu Gu, Tongli Xia, and Xiangtian Kong. Preliminary study of the frequency ofbenign prostatic hyperplasia and prostatic cancer in china. *Urology*, 44(5):688–691, 1994.

[25] Xiudi Sun, Ren Mu, Youshang Zhou, Xudong Dai, Youlin Qiao, Siwei Zhang, Xiaomei Huangfu, Jie Sun, Liandi Li, and Fengzhu Lu. 1990-1992 mortality of stomach cancer in china. *Chinese Journal of Oncology*, 24(1):4, 2002.

[26] Kidong Kim, Rongyu Zang, Seok-Cheol Choi, Sang-Young Ryu, and Jae Weon and Kim. Current status of gynecological cancer in china. *Journal of gynecologic oncology*, 20(2):72–6, 2009.

[27] Wanqing Chen, Rongshou Zheng, Siwei Zhang, Ping Zhao, Guanglin Li, Lingyou Wu, and Jie He. Report of incidence and mortality of brain,nervous system cancer in china,2009. *Chinese Journal of Cancer Research*, 25(1):10–21, 2013.

[28] Wanqing Chen, Rongshou Zheng, Peter D. Baade, Siwei Zhang, Hongmei Zeng, Freddie Bray, Ahmedin Jemal, XueQin Yu, and Jie He. Cancer statistics in china, 2015. *CA: a cancer journal for clinicians*, 66(2):115 – 132, 2016.

[29] Iheanyi E Okpala. *Practical Guidelines on Antibiotic Therapy, Exchange Blood Transfusion and Perioperative Management in Sickle Cell Disease*. Blackwell Publishing Ltd, 2007.

[30] Hazel Tinegate, Janet Birchall, Alexandra Gray, Richard Haggas, and Shubha Allard. Guideline on the investigation and management of acute transfusion reactions prepared by the bcsh blood transfusion task force. *British Journal of Haematology*, 159(2):143–153, 2012.

[31] Helen V. New, Jennifer Berryman, Paula H. B. Bolton-Maggs, Carol Cantwell, and Simon J. Stanworth. Guidelines on transfusion for fetuses, neonates and older children. *British Journal of Haematology*, 175(5):784, 2016.